Celularity Inc.NASDAQ: CELU

Celularity Provides Update Regarding Nasdaq Listing Compliance

· Issued by Celularity Inc. via GlobeNewswire

Summary by 6ix AI

Celularity Inc., a company developing and manufacturing therapies made from cells taken from the placenta, received a letter from Nasdaq on August 21, 2026 saying it is not in compliance with a listing rule because it has not filed its quarterly reports for the periods ended March 31, 2026 and June 30, 2026.

Key details

  • The rule, Nasdaq Listing Rule 5250(c)(1), requires listed companies to file all required periodic financial reports with the U.S. Securities and Exchange Commission on time.
  • The notice has no immediate effect on the listing or trading of the common stock, which continues to trade on the Nasdaq Capital Market under the symbol CELU.
  • Celularity says it is working to complete and file both quarterly reports (Form 10-Q) as soon as practicable.

What’s still pending

  • Nasdaq has asked Celularity to submit a plan to regain compliance by September 4, 2026.
  • Any exception Nasdaq grants would be limited to a maximum of 180 calendar days from the due date of the first late filing, or until November 16, 2026.

6ix AI wrote this summary from the release below and checked it against the release.

FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the "Company") today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that, because the Company has not filed its Quarterly Report on Form 10-Q for the period ended June 30, 2026 and remains delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission.

Nasdaq has requested that the Company submit its plan to regain compliance by September 4, 2026. Any exception granted by Nasdaq will be limited to a maximum of 180 calendar days from the prescribed due date of the initial delinquent filing, or until November 16, 2026.

The notification has no immediate effect on the listing or trading of the Company's common stock, which continues to trade on the Nasdaq Capital Market under the symbol "CELU." The Company is working to complete and file both Quarterly Reports on Form 10-Q as soon as practicable

About Celularity

Celularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing placental-derived cellular therapies. For more information, visit www.celularity.com.

Forward Looking Statements

This press release contains forward-looking statements regarding the Company's ability to complete its delayed filings and regain compliance with Nasdaq's continued listing requirements. Actual results may differ materially due to risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update these statements except as required by law.

Celularity Inc. on 6ix

Story so far

Earlier from Celularity

Later from Celularity

All Celularity news releases